Could an eye implant stop glaucoma from stealing your sight?

NCT ID NCT04577300

Ongoing Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether an implant placed in the eye can slow vision loss in people with glaucoma. The implant releases a protein that may protect nerve cells. Thirty participants will receive either the real implant or a sham procedure and be followed for two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NT-501 encapsulated cell therapy implant (releases ciliary neurotrophic factor)
What this could lead to: If it works, this could point toward a new way to slow vision loss in glaucoma by protecting nerve cells in the eye.
What could go wrong: This is a small, early-phase trial with only 30 people, so results may not apply to everyone. The implant requires surgery and may cause side effects like infection or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLAUCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLAUCOMA

Contacts and locations

Locations

Byers Eye Institute at Stanford University

Palo Alto, California, 94303, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.